864680-64-8

Basic information

• Product Name: tert-butyl 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]acetate
• Synonyms: tert-butyl 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]acetate
• CAS NO: 864680-64-8
• Molecular Weight: 307.387
• Mol File: 864680-64-8.mol

Chemical Properties

• Boiling Point: 386.1±32.0 °C(Predicted)
• Density: 1.051±0.06 g/cm3(Predicted)
• CAS DataBase Reference: tert-butyl 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]acetate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]acetate(864680-64-8)
• EPA Substance Registry System: tert-butyl 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]acetate(864680-64-8)

Safety Data

• Hazardous Substances Data: 864680-64-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]acetate serves as a reagent in organic synthesis, where its unique structure and functional groups facilitate the formation of a variety of complex organic molecules. Its ability to participate in numerous chemical reactions makes it a valuable component in the synthesis of new compounds.
Used in Pharmaceutical Production:
In the pharmaceutical industry, tert-butyl 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]acetate is utilized as a component in the manufacturing process of various drugs. Its functional groups and structural features can be integrated into the molecular frameworks of pharmaceuticals, potentially enhancing their efficacy, stability, or other desirable properties.
Used in Industrial Product Manufacturing:
Beyond its applications in organic synthesis and pharmaceuticals, tert-butyl 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]acetate also finds use in the production of other industrial products. Its versatility and the range of its chemical properties allow it to be incorporated into materials and formulations across different sectors, contributing to the development of innovative and improved products.

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 32503-27-8 tetra(n-butyl)ammonium hydrogensulfate 
• 86770-67-4 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethanol 
• 35059-50-8 t-butyl diazoacetate 
• 90331-86-5 2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]isoindoline-1,3-dione 
• 77544-60-6 p-toluenesulfonic acid 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl ester 
• 112-60-7 Tetraethylene glycol 

Downstream Products

• 2097938-44-6 14-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino]-3,6,9,12-tetraoxatetradecanoic acid 
• 905574-77-8 C₉₄H₁₃₉ClN₁₈O₁₉ 

Relevant articles and documents

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE

The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Amide bond-containing monodisperse polyethylene glycols beyond 10000 da

Although monodisperse polyethylene glycols (M-PEGs) above 4000 Da are especially valuable in biomedical applications, their synthesis remains a long-standing challenge. To this end, a peptide-based strategy for such M-PEGs was developed. With macrocyclic sulfates as the key intermediates, a panel of oligoethylene glycol (OEG) containing ω-amino acids were prepared with high efficiency. Through solid phase peptide synthesis (SPPS), these amino acids were conveniently assembled into a series of amide bond-containing M-PEGs with high flexibility in molecular weight and amide density selection. With this strategy, an M-PEG of 10262 Da was prepared on a gram scale and its biocompatibility was assessed in a mice model.

TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS

The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.

Synthesis and characterization of fluorinated conjugates of albumin

A small fluorocarbon dendron that contains nine chemically identical fluorine atoms was covalently conjugated to albumin via a flexible linker. Two versions were made, which differ by 10% in the linker length. Both versions display split 19F signal and much shorter 19F longitudinal relaxation time than their small molecule counterparts. 10% difference in the flexible linker length has negligible impact on the 19F signal.

Antithrombotic compound

The present invention relates compounds of the formula Aoligosaccharide-spacer-GpIIb/IIIa antagonist wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising four to twenty five monosaccharide units, the charge being compensa